相关实验视频

Updated: Jun 20, 2025

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents

Published on: May 28, 2014

解锁选择性抗癌机制:双核超氧化物脱酶模拟剂与Pt(II) 复合体相结合

Andrea Squarcina¹, Philipp Maier¹, Thibaut Vignane²

¹Department of Chemistry, Ludwig-Maximilians Universität (LMU) München, München, 81377, Germany.

Chemistry (Weinheim an der Bergstrasse, Germany)

|July 22, 2024

概括

双核复合物具有双超氧化物脱酶和酶活性,在癌症治疗中显示出有前途. 与相结合,它们可以选择性地向癌细胞,增强健康细胞的活力,同时减少瘤细胞的存活率.

科学领域:

生物有机化学生物有机化学
催化剂是一种催化剂.
癌症研究癌症研究

背景情况:

双核复合物 (Mn2L2Ac和Mn2L2) 呈现双重超氧化物脱酶 (SOD) 和酶 (CAT) 活动.
单独研究的Mn2复合物和与 (Pt) 复合物 (Pt) 结合的Mn2复合物作为混合物或Mn2-Pt添加物.

研究的目的:

探索Mn2L2Ac和Mn2L2复合物的体外活动,单独和与Pt(II) 复合物.
合成和表征Mn2-Pt添加物以提高治疗潜力.
阐明这些联合治疗的生物效应背后的机制.

主要方法:

合成和表征双核Mn2复合物和Mn2-Pt添加物.
在体外细胞活力测试对健康和乳腺癌细胞进行测试.
评估活性氧物种 (ROS) 含量和细胞 (Mn) 摄入量.
蛋白质组学分析以了解细胞通路调节.

主要成果:

结合Mn2 SOD模仿物和Pt(II) 复合物,可使健康细胞活力提高50%,癌细胞活力降低50%.
孤立的Mn2L2Pt添加物保留了显著的SOD活性 (kSOD=1.7×10^7 M^-1 s^-1).
Mn2配方向线粒体过程,不同影响癌症和健康细胞的蛋白质组.

结论:

含Mn2的配方通过降低H2S信号和线粒体复合体I和III的调节,选择性地影响癌细胞,同时上调氧化酸化和EGFR.
健康细胞表现出EGFR表达率下降和氧化酸化途径中适度丰富.
这些发现凸显了Mn2-Pt组合作为向癌症治疗的潜力.

关键词:

抗瘤剂是一种抗瘤剂.双核催化剂中的一个.金金金是什么意思蛋白质组学蛋白质组学超氧化物解化物

更多相关视频

Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay

Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay

Published on: November 10, 2013

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Published on: February 9, 2021

相关概念视频

Electron Transport Chain: Complex I and II

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...